Literature DB >> 11708498

A framework for the molecular classification of circulating tumor markers.

P J Johnson1.   

Abstract

New molecular biological technologies, especially polymerase chain reaction (PCR) and mass spectroscopy, have expanded the pool of molecular targets for cancer diagnosis, monitoring, and prognosis using plasma or serum as the substrate. In this review, a framework is described following the "life history" of a protein--starting with DNA [endogenous (nuclear or mitochondrial) or exogenous (viral)], followed by RNA [endogenous (cell-based or cell-free) or exogenous (viral)], and culminating in protein (either the native protein or the glycan portion of glycoproteins). Each of these levels provides unique opportunities to achieve specificity for cancer diagnosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11708498     DOI: 10.1111/j.1749-6632.2001.tb03859.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  4 in total

1.  Serum/Plasma depletion with chicken immunoglobulin Y antibodies for proteomic analysis from multiple Mammalian species.

Authors:  Douglas Hinerfeld; David Innamorati; John Pirro; Sun W Tam
Journal:  J Biomol Tech       Date:  2004-09

2.  DNA methylation in repetitive elements and post-traumatic stress disorder: a case-control study of US military service members.

Authors:  Jennifer A Rusiecki; Ligong Chen; Vasantha Srikantan; Lei Zhang; Liying Yan; Matthew L Polin; Andrea Baccarelli
Journal:  Epigenomics       Date:  2012-02       Impact factor: 4.778

3.  A BALB/c murine lung alveolar carcinoma used to establish a surgical spontaneous metastasis model.

Authors:  Michael McLean; Howard L Wallace; Atima Sharma; Hank C Hill; Michael S Sabel; Nejat K Egilmez
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  Tumor markers in clinical practice: General principles and guidelines.

Authors:  S Sharma
Journal:  Indian J Med Paediatr Oncol       Date:  2009-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.